Boston Scientific Corporation Stock News

MARLBOROUGH, Mass. , Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategi

Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.

When you consider healthcare stocks, do you automatically think of pharmaceutical companies? Most people do.

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Boston Scientific (BSX). But which of these two stocks presents

Boston Scientific surprised the Street with better-than-expected ADVENT study results; Farapulse delivered better procedural success rates with good safety and lower procedure times. Farapulse will li

Boston Scientific (BSX) was the best-performing stock in the S&P 500 after the medical device maker reported positive results from a clinical trial for its system to treat patients with atrial fibril

Boston Scientific (NYSE:BSX) shares rose almost 5% after the biotechnology company reported positive results from its pivotal atrial fibrillation (AF) trial. The trial compared the company's FARAPULSE

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.

Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.

Over the near term, the indices are likely to move higher into the 14th. The autumn correction will not be hard on many stocks such as Netflix.

On July 17, 2023, Citadel Advisors LLC (Trades, Portfolio), a prominent investment firm, executed a transaction involving Semper Paratus Acquisition Corp ( LGSTU , Financial). This article provides an

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.

Boston Scientific (BSX) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.44 per share a year ago.

Shares of Boston Scientific Corp. BSX, -0.02% rallied 1.9% in premarket trading Thursday, after the medical technology company beat expectations for both profit and sales, amid strength in its cardiov